Avadel Pharmaceuticals PLC

Avadel Pharmaceuticals PLC

  • Price (USD)7.74
  • Today's Change-0.11 / -1.40%
  • Shares traded706.32k
  • 1 Year change296.92%
  • Beta1.3616
Data delayed at least 15 minutes, as of Aug 11 2020 21:00 BST.
More ▼

Profile data is unavailable for this security.

About the company

Avadel Pharmaceuticals plc is a biopharmaceutical company. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.

  • Revenue in USD (TTM)55.02m
  • Net income in USD-30.20m
  • Incorporated2017
  • Employees50.00
  • Location
    Avadel Pharmaceuticals PLCBlock 10-1 Blanchardstown Corporate ParkBallycoolinDUBLIN 15IrelandIRL
  • Phone+353 14851200
  • Fax+353 15261077
  • Websitehttps://www.avadel.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Satsuma Pharmaceuticals Inc0.00-37.13m434.74m20.00--4.18-----2.16-
Rigel Pharmaceuticals, Inc.108.04m-25.02m439.22m163.00--6.95--4.07-0.1494-0.14940.64270.37420.73450.634611.58662,815.90-17.01-54.29-21.66-69.9599.15---23.16-213.283.21--0.2387--33.2048.365.09--28.64--
Liminal BioSciences Inc2.80m-173.86m439.38m300.001.397.41--156.7113.4114.440.14162.510.02720.26681.049,345.82-169.21-72.42-210.96-93.8038.1051.09-6,218.73-694.982.39-19.190.3899---80.09-26.59-18.19---13.21--
Catalyst Pharmaceuticals Inc119.76m41.77m441.12m76.0010.90--10.543.680.39120.39121.12--1.1416.2813.981,575,806.0039.84-18.0647.66-20.1985.74--34.87-57.246.40--0.00--20,361.27--193.74---19.51--
XBiotech Inc12.68m674.48m450.97m63.001.661.300.666335.569.409.400.273612.030.0637----211,350.00338.7772.46350.2778.0423.71--5,318.82------0.000.00----3,263.16---31.94--
CEL-SCI Corporation519.81k-31.44m452.74m43.00--36.79--870.96-0.9118-0.91180.0150.3270.0175--5.60---105.66-88.53-128.95-119.93-----6,044.45-5,871.522.84-2.690.5197---2.9011.8830.51--11.32--
Clovis Oncology Inc159.36m-385.16m454.69m484.00------2.85-6.07-6.072.44-1.100.24251.479.49329,258.30-58.62-48.66-70.32-56.2675.40---241.69-562.832.63-14.241.20--49.9260.03-8.81--7.55--
Avadel Pharmaceuticals PLC (ADR)55.02m-30.20m456.31m50.00--11.36--8.29-0.7835-0.56131.440.6910.28862.915.101,100,420.00-15.84-5.95-19.01-8.1379.4389.29-54.88-9.643.94-1.130.7936---42.6631.6565.24---55.85--
Rubius Therapeutics Inc0.00-179.36m457.10m195.00--1.94-----2.26-
BioDelivery Sciences International, Inc.136.80m5.79m463.29m178.0087.155.4631.053.390.05270.05271.340.84010.70851.703.75768,556.203.00-30.534.01-42.4482.7473.974.23-50.792.493.040.4801--100.2023.3966.99---45.23--
DURECT Corporation50.07m-1.83m469.35m89.00--12.91--9.37-0.0131-0.01310.25400.18120.75431.2124.19556,300.00-2.76-41.31-3.27-60.3691.3681.42-3.66-81.855.47-0.40740.3611--59.258.7918.73---5.35--
CymaBay Therapeutics Inc0.00-92.82m475.29m24.00--2.72-----1.35-1.350.002.540.00----0.00-40.12-51.60-42.54-59.81-------2,451.13----0.00-------41.71--25.05--
AC Immune SA52.60m-26.93m481.46m115.00--1.76--9.15-0.3763-0.37630.73093.810.1691--99.20457,405.00-8.66-2.57-9.08-2.76-----51.20-9.34---128.150.0093--1,443.3129.68189.1933.4371.25--
AnaptysBio Inc18.00m-81.11m481.99m89.00--1.26--26.78-2.99-2.990.661913.980.0408----202,247.20-18.39-16.74-19.52-17.79-----450.59-347.09----0.00--60.00-12.77-57.87--40.89--
Data as of Aug 11 2020. Currency figures normalised to Avadel Pharmaceuticals PLC's reporting currency: US Dollar USD

Institutional shareholders

32.09%Per cent of shares held by top holders
HolderShares% Held
RTW Investments LPas of 15 Apr 20204.62m7.94%
Avoro Capital Advisor LLCas of 15 Apr 20203.90m6.70%
Acuta Capital Partners LLCas of 31 Mar 20202.67m4.60%
Brandes Investment Partners LPas of 31 Mar 20201.64m2.82%
Cowen & Co. LLCas of 31 Mar 20201.52m2.61%
VHCP Management LLCas of 31 Mar 20201.06m1.82%
Broadfin Capital LLCas of 31 Dec 20191.03m1.77%
Renaissance Technologies LLCas of 31 Mar 2020905.81k1.56%
Invesco Advisers, Inc.as of 31 Mar 2020733.01k1.26%
DWS Investment Management Americas, Inc.as of 31 Mar 2020588.31k1.01%
More ▼
Data from 31 Dec 2019 - 31 Mar 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.